The core characteristics of IGF-1 LR3 Capsule are mainly reflected in three dimensions: "drug activity specificity", "formulation compatibility", and "oral applicability". Firstly, the specificity of drug activity stems from the structural modification advantage of IGF-1 LR3. Compared with natural IGF-1, its N-terminal extended 13 amino acid peptide segment and E3R point mutation reduce its affinity for IGF binding proteins (IGFBPs) to less than 1% of natural IGF-1, extend its half-life from 10 minutes to 20-30 hours, and increase its biological activity by 2-3 times. This characteristic is the basis for its clinical value. Secondly, the compatibility of the formulation is reflected in the protective effect of the capsule form on IGF-1 LR3. By selecting inert excipients and optimizing the filling process, the damage to the peptide molecular structure caused by external environment (temperature, humidity, light) can be reduced, while avoiding direct stimulation between the drug and the gastrointestinal mucosa. Thirdly, oral applicability is its most prominent feature. Compared to injectable forms, capsule administration is convenient, non-invasive, and can significantly improve patients' long-term medication compliance, especially for long-term intervention of chronic diseases.
Our products from
IGF-1 LR3 COA
Molecular pathway of IGF-1 LR3 capsules in regulating gut mucosal permeability by microbiota
The intestinal mucosa is an important interface between the human body and the external environment, and its permeability plays a key role in maintaining the stability of the intestinal environment, preventing pathogen invasion, and regulating nutrient absorption. The abnormal change of intestinal mucosal permeability is closely related to the occurrence and development of many diseases, such as inflammatory bowel disease, irritable bowel syndrome, infectious diseases and systemic inflammatory response syndrome. In recent years, the role of gut microbiota in regulating intestinal mucosal permeability has received widespread attention. The gut microbiota is a complex microbial ecosystem that interacts closely with the host. IGF-1 LR3 is an artificially modified long-acting, highly active insulin-like growth factor analog that plays an important role in promoting cell growth, proliferation, and differentiation. IGF-1 LR3 Capsule, as a potential preparation that may affect gut microbiota and intestinal mucosal permeability, deserves further investigation into its molecular pathway in regulating intestinal mucosal permeability.
The importance and influencing factors of intestinal mucosal permeability
The intestinal mucosa has a barrier function that can prevent harmful substances such as bacteria, toxins, and undigested food particles from entering the bloodstream, while allowing nutrients and water to pass through. The normal maintenance of intestinal mucosal permeability is crucial for protecting the body from pathogen invasion, maintaining immune balance, and ensuring the absorption and utilization of nutrients. When the permeability of the intestinal mucosa increases, harmful substances in the intestine can easily enter the bloodstream, causing systemic inflammatory reactions and leading to the occurrence of various diseases.
Factors affecting intestinal mucosal permeability
The gut microbiota affects intestinal mucosal permeability through various mechanisms. Beneficial bacteria can produce metabolites such as short chain fatty acids, maintain energy supply to intestinal mucosal cells, promote growth and repair of intestinal mucosal cells, and enhance intestinal barrier function. Meanwhile, beneficial bacteria can also competitively inhibit the growth of harmful bacteria, reducing the damage of toxins produced by harmful bacteria to the intestinal mucosa. On the contrary, the proliferation of harmful bacteria can produce toxins and other harmful substances, which can damage the integrity of the intestinal mucosa and increase its permeability.
Cytokines play an important role in regulating intestinal mucosal permeability. Inflammatory cytokines, such as tumor necrosis factor - α (TNF - α), interleukin-1 β (IL-1 β), and interleukin-6 (IL-6), can activate signaling pathways within intestinal mucosal cells, leading to changes in the expression and distribution of tight junction proteins, thereby increasing intestinal mucosal permeability. And anti-inflammatory cytokines, such as interleukin-10 (IL-10), can inhibit the action of pro-inflammatory cytokines and maintain the integrity of intestinal mucosa.
Growth factors play an important role in the growth, repair, and maintenance of barrier function of intestinal mucosa. For example, insulin-like growth factor-1 (IGF-1) can promote the proliferation and differentiation of intestinal mucosal cells, increasing the thickness and integrity of the intestinal mucosa. Epidermal growth factor (EGF) and transforming growth factor alpha (TGF - α) can also activate intracellular signaling pathways and regulate the growth and function of intestinal mucosal cells by binding to corresponding receptors.
Molecular characteristics and mechanism of action of IGF-1 LR3
IGF-1 LR3 is artificially modified based on natural IGF-1. Natural IGF-1 is composed of 70 amino acids and is a single chain alkaline polypeptide. IGF-1 LR3 adds thirteen amino acids to the N-terminus of IGF-1 and replaces the third glutamic acid (Glu) of IGF-1 with arginine (Arg). This structural modification significantly enhances the biological activity and in vivo half-life of IGF-1 LR3. The molecular weight of IGF-1 LR3 is 9.1 kD, which has better growth promoting effects and can promote the division, migration, and differentiation of most cells.
The mechanism of action of IGF-1 LR3
IGF-1 LR3 mainly exerts its function by binding to the insulin-like growth factor-1 receptor (IGF-1R) on the cell surface. After binding, the receptor undergoes autophosphorylation, which recruits and activates phosphatidylinositol 3-kinase (PI3K) through insulin receptor substrate (IRS) protein, thereby activating protein kinase B (Akt). Activated Akt strongly drives protein synthesis and glycogen synthesis by inhibiting key nodes such as glycogen synthase kinase-3 β (GSK-3 β) and activating mammalian rapamycin target protein complex 1 (mTORC1), while inhibiting protein degradation and cell apoptosis. This is the main mechanism by which it promotes cell growth and survival. Meanwhile, IGF-1 LR3 can also activate Ras through the Shc/Grb2/SOS complex, thereby initiating the Raf-MEK-ERK cascade reaction. This pathway mainly regulates cell cycle progression, gene transcription, and cell differentiation, and synergistically promotes cell growth and proliferation with the PI3K pathway. For example, Akt can phosphorylate and inhibit FOXO transcription factors, thereby downregulating the expression of muscle atrophy related genes (such as Atrogin-1, MuRF-1) and exerting anti muscle atrophy effects.
The key role of gut microbiota in regulating intestinal mucosal permeability
The role of beneficial bacteria
Producing short chain fatty acids: Beneficial bacteria such as Bifidobacterium and Lactobacillus can ferment dietary fiber to produce short chain fatty acids, mainly including acetic acid, propionic acid, and butyric acid. Short chain fatty acids are the main energy source for intestinal mucosal cells, which can promote the growth and proliferation of intestinal mucosal cells and enhance intestinal barrier function. Butyric acid can also upregulate the expression of tight junction proteins, maintaining the integrity of intestinal mucosa.
Competitive inhibition of harmful bacteria: Beneficial bacteria can compete with harmful bacteria for nutrients and adhesion sites in the intestine, inhibiting the growth and reproduction of harmful bacteria. For example, bifidobacteria can produce antibacterial substances such as bacteriocins, which directly inhibit the growth of harmful bacteria. Meanwhile, beneficial bacteria can also regulate the pH value in the intestine, creating an environment that is not conducive to the growth of harmful bacteria.
The role of harmful bacteria
Production of endotoxins: Harmful bacteria such as Escherichia coli can produce endotoxins, which are mainly composed of lipopolysaccharides (LPS). LPS can activate Toll like receptor 4 (TLR4) in intestinal mucosal cells, triggering an inflammatory response that alters the expression and distribution of tight junction proteins and increases intestinal mucosal permeability.
Destruction of intestinal mucosal structure: Toxins and enzymes produced by harmful bacteria can directly damage the structure and function of intestinal mucosal cells, leading to intestinal mucosal damage. For example, proteases produced by certain bacteria can degrade tight junction proteins between intestinal mucosal cells, leading to a decrease in the barrier function of the intestinal mucosa.
Molecular pathway of IGF-1 LR3 Capsule microbiota regulating intestinal mucosal permeability
The impact on tight junction proteins
Tight junction proteins are important structural foundations for maintaining intestinal mucosal permeability, mainly including occludin, ZO, and JAM. The IGF-1 LR3 Capsules microbiota can regulate the expression and distribution of tight junction proteins through multiple pathways. IGF-1 LR3 can activate the PI3K/Akt signaling pathway, which upregulates the gene expression of tight junction proteins and promotes their synthesis. Meanwhile, the short chain fatty acids produced by the gut microbiota can also provide energy for intestinal mucosal cells and support the synthesis of tight junction proteins. For example, butyric acid can increase the transcriptional activity of tight junction protein genes by activating histone deacetylase (HDAC) inhibitors. The IGF-1 LR3 Capsules microbiota can regulate the dynamic changes of the cytoskeleton and maintain the normal distribution of tight junction proteins on the cell membrane. Cytoskeleton proteins, such as actin and microtubule proteins, interact with tight junction proteins to maintain the integrity of the intestinal mucosa. IGF-1 LR3 can regulate the rearrangement of the cytoskeleton by activating Rho GTPase family proteins, thereby maintaining the normal distribution of tight junction proteins.
Regulation of cytokines
Cytokines play an important role in regulating intestinal mucosal permeability. The IGF-1 LR3 Capsule microbiota can regulate the balance of pro-inflammatory and anti-inflammatory cytokines, thereby affecting intestinal mucosal permeability. IGF-1 LR3 can inhibit the activation of the NF - κ B signaling pathway and reduce the production of pro-inflammatory cytokines such as TNF - α, IL-1 β, and IL-6. Meanwhile, beneficial bacteria in the gut microbiota can produce anti-inflammatory substances such as IL-10, which inhibit the action of pro-inflammatory cytokines. For example, bifidobacteria can stimulate intestinal mucosal cells to produce IL-10 and inhibit TNF - α - induced damage to intestinal mucosal barrier function. The IGF-1 LR3 Capsules microbiota can also promote the production of anti-inflammatory cytokines and enhance the anti-inflammatory ability of the intestine. IGF-1 LR3 can upregulate the gene expression of anti-inflammatory cytokines such as IL-10 by activating the PI3K/Akt signaling pathway. Meanwhile, certain bacteria in the gut microbiota can stimulate immune cells to produce anti-inflammatory cytokines, maintaining the immune balance of the intestinal mucosa.
Regulation of growth factor signaling pathways
Growth factors play an important role in the growth, repair, and maintenance of barrier function of intestinal mucosa. The IGF-1 LR3 Capsules microbiota can regulate the growth factor signaling pathway, promoting intestinal mucosal repair and regeneration. IGF-1 LR3 itself is an IGF-1 analog that can bind to IGF-1R and activate the IGF-1 signaling pathway. Meanwhile, gut microbiota can regulate the expression and secretion of IGF-1. For example, certain beneficial bacteria can stimulate intestinal mucosal cells to produce IGF-1, enhance the IGF-1 signaling pathway, and promote the proliferation and differentiation of intestinal mucosal cells. The IGF-1 LR3 Capsules microbiota can also synergistically regulate intestinal mucosal permeability with other growth factor signaling pathways. For example, IGF-1 can interact with growth factors such as EGF and TGF - α to regulate cell growth and function through a common signaling pathway. The gut microbiota can regulate the expression and activity of these growth factors, enhancing their protective effect on the intestinal mucosa.
Hot Tags: igf-1 lr3 capsule, China igf-1 lr3 capsule manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, glp 1 agonist injections, glp1 shot, etelcalcetide structure
